Mitopure vs Neurogan: Urolithin A Compared

Mitopure and Neurogan are two of the better-known urolithin A brands, and shoppers often line them up side by side. Both deliver the same active molecule, so the real comparison is about dose, format, testing and value — not about which brand "works." Here is an even-handed way to think it through.

Transparency note: SOMA HEALTH sells its own urolithin A product, so we are a competitor to both Mitopure and Neurogan. Read this comparison with that in mind and apply the same criteria to us.

The same ingredient, two different brands

Both Mitopure (by Timeline) and Neurogan sell urolithin A, so the starting point is understanding the ingredient rather than the label. Urolithin A is a gut postbiotic: your microbiome converts ellagitannins from pomegranate, walnuts and certain berries into it, and only some people convert efficiently. Once in the body it supports mitophagy, the cellular recycling process that clears out worn mitochondria. Because both products contain the same compound, neither brand has a monopoly on the underlying science — the human evidence applies to any product that reaches a clinically studied dose. For the biology, see our urolithin A guide and our overview of mitochondrial health.

Where the two brands differ is in positioning. Mitopure comes from Timeline, the company that funded much of the early human research on urolithin A, and is sold as softgels and as a powder. Neurogan positions itself as a value-focused wellness brand and offers urolithin A in capsule form, with its standard capsule listed at 700 mg per capsule at the time of writing. Because doses, formulations and prices change, confirm the current label for both before buying, and note that we quote only the Neurogan figure we verified in a search for this comparison.

Comparing on the criteria that matter

Dose

Human trials of urolithin A used roughly 500 to 1,000 mg per day, so the key question for either brand is whether the daily serving lands in that range. Neurogan's standard capsule is listed at 700 mg, which sits within the studied range for a single-capsule daily serving; the company also markets other urolithin A formulations, so read the specific product page. Mitopure's softgels are designed to reach a full studied dose across a daily serving — check the current label for exact milligrams. The practical rule for both: add up the total daily amount rather than reading the per-capsule number in isolation.

Testing and quality

Urolithin A is a manufactured, high-purity ingredient, so independent verification matters regardless of brand. Timeline leans heavily on its published research and manufacturing standards; Neurogan states its products are lab tested. When comparing, look for clear third-party testing language on the exact product you are considering, not just a general brand claim.

Format and adherence

Mitopure offers softgels and powder; Neurogan offers capsules. All three are pills or powders you take daily. This is where format preference decides things: if you are comfortable swallowing a capsule or softgel every day, either brand is fine. If you tend to skip pills, adherence suffers, and since urolithin A only helps when taken consistently, a format you will actually stick with matters as much as the milligram count. Our comparison of gummies versus capsules unpacks that trade-off.

Value

Compare the monthly cost to reach a full studied daily dose, not the price of a bottle. A lower price per bottle can still be worse value if the daily dose is smaller or the bottle holds fewer servings. Do the arithmetic for each product: milligrams per daily serving, servings per bottle, and total price, then check the current label since prices shift with promotions and retailers.

What the human evidence supports — for either brand

Because both products deliver urolithin A, the evidence is identical for both at a studied dose; it is not a Mitopure advantage or a Neurogan advantage. The strongest human findings are in muscle. Andreux et al. 2019 (Nature Metabolism), the first-in-human trial, reported that urolithin A was safe and well tolerated at doses up to 1,000 mg per day and produced a mitochondrial gene-expression signature. Singh et al. 2022 (Cell Reports Medicine) tested 500 mg and 1,000 mg arms in middle-aged adults over four months and reported improvements in muscle strength and exercise performance. Liu and D'Amico et al. 2022 (JAMA Network Open) studied older adults over about four months and found gains in muscle endurance, measured as contractions before fatigue.

More recent human trials continue to broaden the evidence: a 2024 randomized trial in the Journal of the International Society of Sports Nutrition looked at endurance and recovery markers in resistance-trained men over eight weeks, and a 2025 randomized trial in Nature Aging reported support for immune-cell mitochondrial health in midlife adults over roughly 28 days. The balanced conclusion, consistent with a 2024 systematic review in Ageing Research Reviews, is that the human evidence is promising but still emerging, resting on short trials and modest sample sizes.

A large share of the enthusiasm for urolithin A comes from preclinical research, which should be labeled clearly. Ryu et al. 2016 (Nature Medicine) is foundational: it established mitophagy, extended lifespan in C. elegans and improved muscle function in rodents — animal and cell data, not human proof. D'Amico et al. 2022 (Aging Cell) examined joint and cartilage mitochondrial health in osteoarthritis models, also in animals. Skin, gut, brain and heart applications remain early or preclinical, where research is exploring possibilities rather than proving human outcomes. Urolithin A supports muscle and mitochondrial health; it is not a treatment for any disease, and nothing here is a treatment claim. If you have a medical condition or take medication, see your doctor before starting. Our best urolithin A gummies roundup applies the same evidence lens to specific products.

How to choose between them

Neither Mitopure nor Neurogan is the automatic winner, because both deliver the same molecule. Lean toward Mitopure if you value Timeline's research pedigree and are happy with softgels or powder. Lean toward Neurogan if you want a capsule and are optimizing for value, and confirm its 700 mg (or other) dose against the studied range on the exact product page. And if a pill format is the barrier, a gummy that reaches the same studied 1,000 mg range may serve adherence better than either. Score each on four numbers — daily milligrams, third-party testing, format you will stick with, and monthly cost per studied dose — and let those decide, not the branding.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.